CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Clinical trial NCT03275493 · UNKNOWN

Trial details

NCT number: NCT03275493
Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia CD19 Positive Relapse Refractory

Start date: 2017-07-01
Primary completion: 2024-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.